Biofrontera Inc. BFRI
Nov 4, 2026, 1:33 PM EST
- YTD
- +53.77%
- 1 year
- -14.90%
- Market cap
- 13.02M
- Revenue (ttm)
- 35.24M
- Profit margin
- -38.34%
- EPS (ttm)
- -0.43
- Shares out
- 7.75M
- Forward P/E
- -1.17
- YTD return
- +53.77%
- 1-year return
- -14.90%
- Volume
- 48.95K
- Avg volume
- 494.42K
- Open
- 0.8889
- Previous close
- 0.8899
- Day's range
- 0.86 – 0.93
- 52-week range
- 0.555 – 1.66
- Beta
- 0.51
- Price target
- 11.50 (+1212.0%)
- Earnings date
- Aug 14, 2024
YTD +0.1490 (+20.55%)
Key statistics
- Enterprise value
- 959.18K
- PEG ratio
- 0.00
- Price / sales
- 0.22
- Price / book
- 0.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 34.00%
- Free cash flow
- -17.96M
- Total cash
- 4.39M
- Total debt
- 1.44M
- Return on equity
- -149.41%
- Short % of float
- 8.26%
- 50-day average
- 0.93324
- 200-day average
- 1.17
Analyst view
- Target (low)
- 7.00
- Target (mean)
- 11.50
- Target (high)
- 16.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.07.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.73 | -0.86 | -0.13 | -17.81% |
| Aug 14, 2024 | Jun 1, 2024 | -1.19 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -1.19 | -1.12 | +0.07 | +5.88% |
| May 15, 2024 | Mar 1, 2024 | -1.63 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -1.63 | -1.85 | -0.22 | -13.50% |
| Mar 15, 2024 | Dec 1, 2023 | 0.00 | -2.33 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | Benchmark | reit | Buy | Buy |
| Aug 16, 2024 | Benchmark | reit | Buy | Buy |
| Aug 31, 2023 | Benchmark | reit | Buy | Buy |
About Biofrontera Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- biofrontera-us.com
News
Biofrontera Refiles Supplemental New Drug Application For Ameluz Topical Gel To FDA To Treat Actinic Keratoses 
Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body 
12 Health Care Stocks Moving In Monday's After-Market Session 
Biofrontera (NASDAQ:BFRI) & Astrazeneca (NYSE:AZN) Critical Contrast 
Transcript: Biofrontera Q2 2026 Earnings Conference Call 
Biofrontera Receives FDA Supplemental New Drug Application Approval For Its Ameluz Topical Gel, 10%, In Combination With Photodynamic Therapy Using The BF-RhodoLED Lamp Series For The Treatment Of Superficial Basal Cell Carcinoma In Adults 
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript 
Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates
Your note
Sign in to keep a note on BFRI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| LUEBBERT HERMANN | Chief Executive Officer | Conversion of Exercise of derivative security | May 16, 2024 | 15,211 |
| MONACO ERICA L. | Chief Executive Officer | Conversion of Exercise of derivative security | May 17, 2023 | 133,025 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AIGH Capital Management LLC | 6.47% | 501,434 | 506.45K | Sep 29, 2024 |
| Rosalind Advisors, Inc. | 6.39% | 495,490 | 500.44K | Sep 29, 2024 |
| Scotia Capital Inc. | 0.65% | 50,000 | 50.50K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.22% | 17,102 | 17.27K | Sep 29, 2024 |
| Blackrock Inc. | 0.06% | 4,622 | 4.67K | Sep 29, 2024 |
| UBS Group AG | 0.04% | 3,099 | 3.13K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.19% | 14,858 | 15.01K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.11% | 8,611 | 8.70K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 3,733 | 3.77K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.01% | 422 | 426 | Oct 30, 2024 |